BACKGROUND: Few studies have investigated metabolic complications in HIV-infected African children and their relation with inflammation. METHODS: We compared baseline and changes in insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR)] and in markers of inflammation over 48 weeks, in a subset of antiretroviral therapy (ART)-naive Ugandan children from the Children with HIV in Africa-Pharmacokinetics and Adherence/Acceptability of Simple Antiretroviral Regimens trial randomized to zidovudine-, stavudine- or abacavir (ABC)-based regimen. Nonparametric methods were used to explore between-group and within-group differences, and multivariable analysis to assess associations of HOMA-IR. RESULTS:One-hundred eighteen children were enrolled, and median age (interquartile range) was 2.8 years (1.7-4.3). Baseline median HOMA-IR (interquartile range) was 0.49 (0.38-1.07) and similar between the arms. At week 48, median relative changes in HOMA-IR were 14% (-29% to 97%) in the zidovudine arm, -1% (-30% to 69%) in the stavudine arm and 6% (-34% to 124%) in the ABC arm (P ≤ 0.03 for all the arms compared with baseline, but P = 0.90 for between-group differences). Several inflammation markers significantly decreased in all study arms; soluble CD14 increased on ABC and did not change in the other 2 arms. In multivariate analysis, only changes in soluble CD163 were positively associated with HOMA-IR changes. CONCLUSIONS: In ART-naive Ugandan children, HOMA-IR changed significantly after 48 weeks of ART and correlated with monocyte activation.
RCT Entities:
BACKGROUND: Few studies have investigated metabolic complications in HIV-infected African children and their relation with inflammation. METHODS: We compared baseline and changes in insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR)] and in markers of inflammation over 48 weeks, in a subset of antiretroviral therapy (ART)-naive Ugandan children from the Children with HIV in Africa-Pharmacokinetics and Adherence/Acceptability of Simple Antiretroviral Regimens trial randomized to zidovudine-, stavudine- or abacavir (ABC)-based regimen. Nonparametric methods were used to explore between-group and within-group differences, and multivariable analysis to assess associations of HOMA-IR. RESULTS: One-hundred eighteen children were enrolled, and median age (interquartile range) was 2.8 years (1.7-4.3). Baseline median HOMA-IR (interquartile range) was 0.49 (0.38-1.07) and similar between the arms. At week 48, median relative changes in HOMA-IR were 14% (-29% to 97%) in the zidovudine arm, -1% (-30% to 69%) in the stavudine arm and 6% (-34% to 124%) in the ABC arm (P ≤ 0.03 for all the arms compared with baseline, but P = 0.90 for between-group differences). Several inflammation markers significantly decreased in all study arms; soluble CD14 increased on ABC and did not change in the other 2 arms. In multivariate analysis, only changes in soluble CD163 were positively associated with HOMA-IR changes. CONCLUSIONS: In ART-naive Ugandan children, HOMA-IR changed significantly after 48 weeks of ART and correlated with monocyte activation.
Authors: Todd T Brown; Stephen R Cole; Xiuhong Li; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: Arch Intern Med Date: 2005-05-23
Authors: Ari Bitnun; Etienne Sochett; Paul T Dick; Teresa To; Craig Jefferies; Paul Babyn; Jack Forbes; Stanley Read; Susan M King Journal: J Clin Endocrinol Metab Date: 2004-10-13 Impact factor: 5.958
Authors: Phyllis C Tien; Michael F E Schneider; Stephen R Cole; Alexandra M Levine; Mardge Cohen; Jack DeHovitz; Mary Young; Jessica E Justman Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Caroline J Chantry; Michael D Hughes; Carmelita Alvero; Joseph S Cervia; William A Meyer; Janice Hodge; Peggy Borum; Jack Moye Journal: Pediatrics Date: 2008-06-02 Impact factor: 7.124
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Stephane De Wit; Caroline A Sabin; Rainer Weber; Signe Westring Worm; Peter Reiss; Charles Cazanave; Wafaa El-Sadr; Antonella d'Arminio Monforte; Eric Fontas; Matthew G Law; Nina Friis-Møller; Andrew Phillips Journal: Diabetes Care Date: 2008-02-11 Impact factor: 17.152
Authors: Jennifer Jao; Denise L Jacobson; Wendy Yu; William Borkowsky; Mitchell E Geffner; Elizabeth J McFarland; Kunjal Patel; Paige L Williams; Tracie Miller Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: S Dirajlal-Fargo; L Shan; A Sattar; E Bowman; J Gabriel; M Kulkarni; N Funderburg; R Nazzinda; V Musiime; G A McComsey Journal: HIV Med Date: 2019-10-23 Impact factor: 3.180
Authors: Lisa J Frigati; Jennifer Jao; Sana Mahtab; Nana-Akua Asafu Agyei; Mark F Cotton; Landon Myer; Heather J Zar Journal: AIDS Res Hum Retroviruses Date: 2018-09-25 Impact factor: 2.205
Authors: Greg S Gojanovich; Denise L Jacobson; Jennifer Jao; Jonathan S Russell; Russell B Van Dyke; Daniel E Libutti; Tanvi S Sharma; Mitchell E Geffner; Mariana Gerschenson Journal: AIDS Res Hum Retroviruses Date: 2020-07-20 Impact factor: 2.205
Authors: Renee Margossian; Paige L Williams; Wendy Yu; Denise L Jacobson; Mitchell E Geffner; Linda A DiMeglio; Russell B Van Dyke; Stephen A Spector; Gertrud U Schuster; Charles B Stephensen; Tracie L Miller; Steven E Lipshultz Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731